By putting its foot in the door at the FDA, can 23andMe reinvigorate direct-to-consumer genomics? Malorye Allison investigates.
This is a preview of subscription content, log in via an institution to check access.
References
The American College of Obstetricians and Gynecologists. Committee Opinion on Personalized Genomic Testing for Disease Risk. June, 2012. http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Genetics/Personalized_Genomic_Testing_for_Disease_Risk
Allison, M. Nat. Biotechnol. 28, 633 (2010).
Eriksson, N. PLoS Genet. 6, e1000993 (2010).
Harmon, A. Gene map becomes a luxury item. New York Times, March 4, 2008. http://www.nytimes.com/2008/03/04/health/research/04geno.html?_r=0
DeFrancesco, L. & Subbaraman, N. Nat. Biotechnol. 29, 379–380 (2011).
Roberts, N.J. et al. Sci. Transl. Med. 4, 133ra58 (2012).
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 (PDF 32 kb)
Rights and permissions
About this article
Cite this article
Allison, M. Direct-to-consumer genomics reinvents itself. Nat Biotechnol 30, 1027–1029 (2012). https://doi.org/10.1038/nbt.2409
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2409
- Springer Nature America, Inc.
This article is cited by
-
Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making
Genome Medicine (2021)
-
Predictors of adverse psychological experiences surrounding genome-wide profiling for disease risk
Journal of Community Genetics (2018)
-
Falling prices and unfair competition in consumer genomics
Nature Biotechnology (2013)
-
Direct-to-Consumer Genetic Testing and Personal Genomics Services: A Review of Recent Empirical Studies
Current Genetic Medicine Reports (2013)